Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) EBIT (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed EBIT for 11 consecutive years, with -$98.7 million as the latest value for Q4 2025.

  • On a quarterly basis, EBIT rose 27.66% to -$98.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$441.0 million, a 17.46% increase, with the full-year FY2025 number at -$441.0 million, up 17.46% from a year prior.
  • EBIT was -$98.7 million for Q4 2025 at Intellia Therapeutics, up from -$111.5 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$46.4 million in Q1 2021 to a low of -$144.8 million in Q3 2024.
  • A 5-year average of -$110.8 million and a median of -$111.7 million in 2023 define the central range for EBIT.
  • Peak YoY movement for EBIT: crashed 210.71% in 2022, then increased 27.66% in 2025.
  • Intellia Therapeutics' EBIT stood at -$80.4 million in 2021, then crashed by 36.9% to -$110.1 million in 2022, then fell by 27.07% to -$139.9 million in 2023, then increased by 2.46% to -$136.4 million in 2024, then increased by 27.66% to -$98.7 million in 2025.
  • Per Business Quant, the three most recent readings for NTLA's EBIT are -$98.7 million (Q4 2025), -$111.5 million (Q3 2025), and -$110.0 million (Q2 2025).